M J Whitley1, D M Henke2, A Ghazi2, M Nieman3, M Stoller4, L M Simon2, E Chen2, J Vesci1, M Holinstat5, S E McKenzie1, C A Shaw2,6, L C Edelstein1, P F Bray4. 1. The Cardeza Foundation for Hematologic Research and the Department of Medicine, Thomas Jefferson University, Jefferson Medical College, Philadelphia, PA, USA. 2. Department of Human & Molecular Genetics, Baylor College of Medicine, Houston, TX, USA. 3. Department of Pharmacology, Case Western Reserve University, Cleveland, OH, USA. 4. Program in Molecular Medicine and the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA. 5. Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA. 6. Department of Statistics, Rice University, Houston, TX, USA.
Abstract
Essentials The rs773902 SNP results in differences in platelet protease-activated receptor (PAR4) function. The functional consequences of rs773902 were analyzed in human platelets and stroke patients. rs773902 affects thrombin-induced platelet function, PAR4 desensitization, stroke association. Enhanced PAR4 Thr120 effects on platelet function are blocked by ticagrelor. SUMMARY: Background F2RL3 encodes protease-activated receptor (PAR) 4 and harbors an A/G single-nucleotide polymorphism (SNP) (rs773902) with racially dimorphic allelic frequencies. This SNP mediates an alanine to threonine substitution at residue 120 that alters platelet PAR4 activation by the artificial PAR4-activation peptide (PAR4-AP) AYPGKF. Objectives To determine the functional effects of rs773902 on stimulation by a physiological agonist, thrombin, and on antiplatelet antagonist activity. Methods Healthy human donors were screened and genotyped for rs773902. Platelet function in response to thrombin was assessed without and with antiplatelet antagonists. The association of rs773902 alleles with stroke was assessed in the Stroke Genetics Network study. Results As compared with rs773902 GG donors, platelets from rs773902 AA donors had increased aggregation in response to subnanomolar concentrations of thrombin, increased granule secretion, and decreased sensitivity to PAR4 desensitization. In the presence of PAR1 blockade, this genotype effect was abolished by higher concentrations of or longer exposure to thrombin. We were unable to detect a genotype effect on thrombin-induced PAR4 cleavage, dimerization, and lipid raft localization; however, rs773902 AA platelets required a three-fold higher level of PAR4-AP for receptor desensitization. Ticagrelor, but not vorapaxar, abolished the PAR4 variant effect on thrombin-induced platelet aggregation. A significant association of modest effect was detected between the rs773902 A allele and stroke. Conclusion The F2RL3 rs773902 SNP alters platelet reactivity to thrombin; the allelic effect requires P2Y12 , and is not affected by gender. Ticagrelor blocks the enhanced reactivity of rs773902 A platelets. PAR4 encoded by the rs773902 A allele is relatively resistant to desensitization and may contribute to stroke risk.
Essentials The rs773902 SNP results in differences in platelet protease-activated receptor (PAR4) function. The functional consequences of rs773902 were analyzed in human platelets and strokepatients. rs773902 affects thrombin-induced platelet function, PAR4 desensitization, stroke association. Enhanced PAR4Thr120 effects on platelet function are blocked by ticagrelor. SUMMARY: Background F2RL3 encodes protease-activated receptor (PAR) 4 and harbors an A/G single-nucleotide polymorphism (SNP) (rs773902) with racially dimorphic allelic frequencies. This SNP mediates an alanine to threonine substitution at residue 120 that alters platelet PAR4 activation by the artificialPAR4-activation peptide (PAR4-AP) AYPGKF. Objectives To determine the functional effects of rs773902 on stimulation by a physiological agonist, thrombin, and on antiplatelet antagonist activity. Methods Healthy human donors were screened and genotyped for rs773902. Platelet function in response to thrombin was assessed without and with antiplatelet antagonists. The association of rs773902 alleles with stroke was assessed in the Stroke Genetics Network study. Results As compared with rs773902 GG donors, platelets from rs773902 AA donors had increased aggregation in response to subnanomolar concentrations of thrombin, increased granule secretion, and decreased sensitivity to PAR4 desensitization. In the presence of PAR1 blockade, this genotype effect was abolished by higher concentrations of or longer exposure to thrombin. We were unable to detect a genotype effect on thrombin-induced PAR4 cleavage, dimerization, and lipid raft localization; however, rs773902 AA platelets required a three-fold higher level of PAR4-AP for receptor desensitization. Ticagrelor, but not vorapaxar, abolished the PAR4 variant effect on thrombin-induced platelet aggregation. A significant association of modest effect was detected between the rs773902 A allele and stroke. Conclusion The F2RL3rs773902 SNP alters platelet reactivity to thrombin; the allelic effect requires P2Y12 , and is not affected by gender. Ticagrelor blocks the enhanced reactivity of rs773902 A platelets. PAR4 encoded by the rs773902 A allele is relatively resistant to desensitization and may contribute to stroke risk.
Authors: Timothy J Stalker; John D Welsh; Maurizio Tomaiuolo; Jie Wu; Thomas V Colace; Scott L Diamond; Lawrence F Brass Journal: Blood Date: 2014-06-20 Impact factor: 22.113
Authors: S L French; J F Arthur; H Lee; W S Nesbitt; R K Andrews; E E Gardiner; J R Hamilton Journal: J Thromb Haemost Date: 2016-06-22 Impact factor: 5.824
Authors: Pierluigi Tricoci; Megan Neely; Michael J Whitley; Leonard C Edelstein; Lukas M Simon; Chad Shaw; Paolo Fortina; David J Moliterno; Paul W Armstrong; Philip Aylward; Harvey White; Frans Van de Werf; Lisa K Jennings; Lars Wallentin; Claes Held; Robert A Harrington; Kenneth W Mahaffey; Paul F Bray Journal: Blood Cells Mol Dis Date: 2018-07-21 Impact factor: 3.039
Authors: Leonard C Edelstein; Lukas M Simon; Raúl Teruel Montoya; Michael Holinstat; Edward S Chen; Angela Bergeron; Xianguo Kong; Srikanth Nagalla; Narla Mohandas; David E Cohen; Jing-fei Dong; Chad Shaw; Paul F Bray Journal: Nat Med Date: 2013-11-10 Impact factor: 53.440
Authors: Xu Han; Lukas Hofmann; Maria de la Fuente; Nathan Alexander; Krzysztof Palczewski; Marvin T Nieman Journal: Blood Date: 2020-11-05 Impact factor: 25.476
Authors: Dian Ningtyas; Russell J Thomson; Volga Tarlac; Shivashankar H Nagaraj; Wendy Hoy; John D Mathews; Simon J Foote; Elizabeth E Gardiner; Justin R Hamilton; Brendan J McMorran Journal: Front Genet Date: 2020-04-30 Impact factor: 4.599
Authors: Laura J Corbin; Stephen J White; Amy E Taylor; Christopher M Williams; Kurt Taylor; Marion T van den Bosch; Jack E Teasdale; Matthew Jones; Mark Bond; Matthew T Harper; Louise Falk; Alix Groom; Georgina G J Hazell; Lavinia Paternoster; Marcus R Munafò; Børge G Nordestgaard; Anne Tybjærg-Hansen; Stig E Bojesen; Caroline Relton; Josine L Min; George Davey Smith; Andrew D Mumford; Alastair W Poole; Nicholas J Timpson Journal: Circ Res Date: 2022-01-11 Impact factor: 23.213